VIDEO: Benefits from SGLT2 inhibitors 'cover the whole continuum of heart failure care'
Click Here to Manage Email Alerts
Biykem Bozkurt, MD, PhD, the Mary and Gordon Cain Chair and Professor of Medicine at Baylor College of Medicine, spoke with Healio about results from trials on HF presented at the American Heart Association Scientific Sessions.
Bozkurt, who also is director of the Winters Center for Heart Failure Research, discussed findings from the EMPULSE trial assessing empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) among hospitalized patients with acute HF and the EMPEROR-Preserved trial, evaluating empagliflozin in patients who had HF with preserved ejection fraction. She also detailed findings from the DREAM-HF trial and the CHIEF-HF trial, which was entirely remote.
“Overall, the message that we gain from this portfolio of trials are we have new models of care and new models of trial design,” Bozkurt said. “One is the SGLT2 benefit seems to cover the whole continuum of heart failure care, demonstrating benefit in pre-heart failure, heart failure, and among, also, hospitalized heart failure patients.
“In trial design, we have some innovation of being able to do a design that is totally [virtual], that can be completed in a very effective time frame, with measurable outcomes,” she said.
References:
Butler J, et al. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection: The EMPEROR-Preserved Trial.
Perin EC, et al. LBS.05. Building on the Foundations of Treatment: Advances in Heart Failure Therapy.
Spertus J, et al. LBS.05. Building on the Foundations of Treatment: Advances in Heart Failure Therapy.
Voors A, et al. LBS.05. Building on the Foundations of Treatment: Advances in Heart Failure Therapy. All presented at: American Heart Association Scientific Sessions; Nov. 13-15, 2021 (virtual meeting).
Collapse
Read more about
Click Here to Manage Email Alerts